Geneyx Joins UK Government G-Cloud 15 Framework, Expanding UK Access to AI-Powered Genomic Analysis

New listing gives NHS organizations, public-sector genomic laboratories and research institutions a streamlined route to procure Geneyx's AI-driven platform for short- and long-read genomic analysis, multi-omics and interpretation

Herzliya, Israel — 18 August 2026 — Geneyx Genomex Ltd., a global provider of genomic analysis and interpretation solutions, today announced that it has been approved as a supplier on the UK Government's G-Cloud 15 framework.

The listing provides eligible UK public-sector organizations with a streamlined procurement route to Geneyx's cloud-based genomic analysis and interpretation software through the Government's G-Cloud framework.

For NHS genomic services, hospital laboratories and research institutions facing increasing volumes and complexity of sequencing data, Geneyx provides a unified environment for analyzing and interpreting genomic information across multiple sequencing technologies and data types.

Geneyx's cloud-based next-generation sequencing (NGS) platform combines AI-powered agentic workflows, long- and short-read analysis, and multi-omics integration across DNA, RNA and epigenetic data.

Geneyx's agentic workflows go beyond individual AI-assisted tasks. They are designed to coordinate and automate multi-step genomic analysis and interpretation processes, applying AI across successive stages of the workflow to help laboratories move from complex sequencing data towards prioritized, interpretable findings more efficiently.

This approach is particularly relevant as genomic laboratories increasingly move beyond conventional short-read sequencing towards long-read technologies and integrated multi-omics analysis, creating larger and more complex datasets that require scalable interpretation.

David Yizhar, CEO of Geneyx Genomex Ltd., said:

"Joining G-Cloud 15 is an important step in expanding access to Geneyx across the UK. Genomic laboratories are being asked to interpret more samples, more complex sequencing data and an expanding range of genomic technologies, while maintaining the accuracy and consistency required for clinical and research applications.

"Our inclusion on G-Cloud 15 gives eligible UK organizations a more straightforward procurement route to Geneyx and to our AI-powered agentic workflows, long-read capabilities and integrated multi-omics analysis."

Geneyx supports genomic analysis and interpretation across rare and inherited diseases and oncology, enabling laboratories to work with both short- and long-read sequencing within a scalable cloud-based environment.

Its multi-omics capabilities enable DNA, RNA and epigenetic information to be analyzed within an integrated workflow, helping researchers and genomic specialists investigate findings that may not be fully resolved by a single data type alone.

Geneyx currently serves more than 5,500 users in 55 countries, supporting healthcare institutions, genetic laboratories, research centers and national genomic programs worldwide. To date, more than 694,000 genomic analyses have been performed on the Geneyx platform, demonstrating its ability to support genomic programs and laboratories operating at scale.

G-Cloud 15 is the latest generation of the UK Government's framework for procuring cloud-based computing services, including cloud software, hosting and support. Operating under the Procurement Act 2023, the framework provides public-sector organizations with access to approved cloud suppliers and is designed to offer a quick and easy route to market.

Geneyx's G-Cloud 15 supplier listing:
https://www.applytosupply.digitalmarketplace.service.gov.uk/g-cloud-15/supplier/723633

More information about G-Cloud 15:
https://www.gca.gov.uk/agreements/RM1557.15

About Geneyx Genomex Ltd.

Geneyx is a global digital health company focused on redefining clinical genomics through AI-driven, high-throughput next-generation sequencing analysis and interpretation.

Its scalable platform combines AI-powered analysis with short- and long-read sequencing and multi-omics capabilities to support rapid, accurate and cost-effective genomic interpretation across rare and inherited diseases and oncology.

Geneyx serves more than 5,500 users in 55 countries, with more than 694,000 genomic analyses performed on its platform to date. The company supports healthcare institutions, research centers and national genomic programs worldwide. Through collaborations with leading sequencing, technology and healthcare organizations, Geneyx is working to accelerate the adoption of genomic medicine and precision healthcare.

To learn more, visit www.geneyx.com.

Media contact:

Dr. Suzie Drury

Product Manager

email: [email protected]

Phone: +447800533005